NCT04329650View on ClinicalTrials.gov

Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia

PHASE2CompletedINTERVENTIONAL

Enrollment

163

Participants

Timeline

Start Date

April 15, 2020

Primary Completion Date

February 26, 2021

Study Completion Date

February 26, 2021

Conditions

COVID-19

Interventions

DRUG

Siltuximab

A single-dose of 11mg/Kg of siltuximab will be administered by intravenous infusion.

DRUG

Dexamethasone

A dose of 6mg/24 hours of dexamethasone during 10 days will be administered orally or by intravenous infusion.

Trial Locations (4)

Unknown

Hospital Germans Trias i Pujol, Badalona

Hospital Universitario de Salamanca, Salamanca

Hospital Universitari Mútua de Terrassa, Terrassa

08036

Hospital Clínic de Barcelona, Barcelona

All Listed Sponsors

lead

Judit Pich Martínez

OTHER

NCT04329650 - Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia | Biotech Hunter | Biotech Hunter